This LaunchTrends report series will track the post-launch awareness, trial, and usage of Apremilast (Otezla) among rheumatologists for the treatment of Psoriatic Arthritis. Three waves of the syndicated report will assess physician perceptions at one month, six months and one year after the launch of Apremilast. The reports will further explore where Apremilast is being placed in the treatment algorithm and in which patient types, strengths and weaknesses of the product profile compared to other agents, and the overall impact of the launch on the market landscape.

Questions Answered in This Report:

  • What is the awareness (aided/unaided), level of familiarity and usage of Apremilast?


  • What are the demographic characteristics of Apremilast users?


  • Among users, at what point in the treatment algorithm and for which patients are they prescribing the product?


  • Is Apremilast competing with TNF inhibitors for first-line biologic use? Or is it being relegated to later lines of therapy?


  • How do physicians anticipate their usage of Apremilast to change going forward?


  • What messages do physicians recall for the promotion of Apremilast?


  • Promotionally speaking, how is the manufacturer positioning their product in the marketplace vs. other products?

Scope:

Sample Methodology:

~75-100 Rheumatologists complete a 30-minute online quantitative sur-vey with several open-ended questions for qualitative feedback. In addi-tion, ten surveyed specialists participate in a 30-minute qualitative inter-view.

To qualify, repondents must meet the following criteria:

- Minimum of 50 PsA patients under management

- Minimum of 25 PsA patients treated with a biologic

- Have been in practice a minimum of two years and a maximum of 30 years

- More than 75 percent of professional time spent in clinical practice -

Deliverables:

- Final report in PowerPoint format

- Complete set of frequency tables, summary statistics, and cross tabulations can be provided upon request

- Transcripts of qualitative interviews can be provided upon request

- Proprietary question slide deck: Clients purchasing report prior to fielding will have the opportunity to include up to three proprietary questions in each wave

Physician Research:

- 75 rheumatologists for the first two waves

- 100 rheumatologists for the third wave

Key Drugs Covered:

- Cimzia, Enbrel, Humira, Orencia, Remicade, Rituxan, Simponi, Stelara, Apremilast

Key Companies Mentioned:

- Celgene, Janssen, Amgen, AbbVie, and UCB

Related Reports:

LaunchTrends®: Stelara (US), Psoriatic Arthritis

DecisionBase®: Psoriatic Arthritis

Pharmacor®: Psoriatic Arthritis

PatientBase®: Psoriatic Arthritis in G7

PatientBase®: Psoriatic Arthritis in Mexico

PatientBase®: Psoriatic Arthritis in Turkey

PatientBase®: Psoriatic Arthritis in South Korea

PatientBase®: Psoriatic Arthritis in Brazil

PatientBase®: Psoriatic Arthritis in Russia

PatientBase®: Psoriatic Arthritis in India

PatientBase®: Psoriatic Arthritis in China


Related Reports

Psoriatic Arthritis - Landscape & Forecast - Disease Landscape & Forecast

A series of launches are expected to continue to impact the increasingly dynamic psoriatic arthritis (PsA) therapy market in the next ten years and...

View Details

Psoriatic Arthritis | Disease Landscape and Forecast | G7 | 2020

A series of launches are expected to impact the increasingly dynamic psoriatic arthritis (PsA) therapy market over the next 10 years and challenge the dominance of the TNF inhibitors; the...

View Details

Psoriatic Arthritis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis (US) Dashboard

Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (

View Details

Psoriatic Arthritis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms - Claims Data Analysis (US)

Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (

View Details